Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin.

Seventeen patients with advanced, previously treated Hodgkin's disease received therapy with a combination of streptozotocin 500 mg/m2/day i.v. days 1--5, CCNU 100 mg/m2 orally day 1, adriamycin 45 mg/m2 i.v. day 1, and bleomycin 15 mg/m2 i.m. days 1 and 8 at 28-day intervals (SCAB). The overall response rate was 59% with six patients (35%) achieving complete remission and four patients (24%) entering partial remissions. No maintenance therapy was given and the median duration of complete remission was 8+ months (range 2+-18+ months), while the median duration of partial remission was only 2 months (range 2-3 months). The median duration of survival from the start of therapy for the complete responders was 16+ months (range 5+-25+ months) while the median survival for the partial and nonresponders was only 5 months (range 2-13 and 3-11+ months, respectively). Toxicity was a major problem with this drug combination. Myelosuppression occurred regularly and was severe after 25% of courses. There were two deaths directly related to drug-induced myelosuppression. Other serious toxicities included bleomycin-induced pulmonary toxicity in three patients, with one death; renal tubular dysfunction secondary to streptozotocin in three patients; hepatic dysfunction in three patients and severe weight loss in three. SCAB has proven to be an active although toxic combination which is not cross-resistant to MOPP-type regimens. Alterations in drug dosages and scheduling are being evaluated in an effect to ameliorate toxicity and preserve efficacy.

[1]  L. Kvols,et al.  Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease , 1977, Cancer.

[2]  N. Bachur,et al.  Combination chemotherapy with adriamycin and streptozotocin; II. Clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin , 1976, Clinical pharmacology and therapeutics.

[3]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[4]  T. Phillips,et al.  Modification of radiation injury to normal tissues by chemotherapeutic agents , 1975, Cancer.

[5]  V. Devita,et al.  Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998) , 1974, Cancer.

[6]  S K Carter,et al.  Adriamycin. A new anticancer drug with significant clinical activity. , 1974, Annals of internal medicine.

[7]  S. Carter,et al.  Combination chemotherapy of advanced Hodgkin's disease. A review , 1974, Cancer.

[8]  R. Benjamin,et al.  Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule , 1974, Cancer.

[9]  O. Glidewell,et al.  Multiple chemotherapeutic agents for Hodgkin disease. Comparison of three routines: a cooperative study by acute leukemia group B. , 1973, JAMA.

[10]  E. Gehan,et al.  Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission. , 1973, Annals of internal medicine.

[11]  J. Durant,et al.  Development of four‐drug bcnu combination chemotherapy regimens. (Writing committee for southeastern cancer study group) , 1973, Cancer.

[12]  B. Hoogstraten,et al.  CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosourea, NSC‐79037) in the treatment of cancer. Phase II study , 1973, Cancer.

[13]  S. Carter,et al.  A clinical review of bleomycin—a new antineoplastic agent , 1973, Cancer.

[14]  V. Devita,et al.  A decade of combination chemotherapy of advanced Hodgkin's disease , 1972, Cancer.

[15]  V. Devita,et al.  Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. , 1971, The New England journal of medicine.